Prime Minister's Intervention On Patents And Data Protection Issue Sparks Fresh Row Between Indian And Multinational Drug Makers
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Leading multinational and India drug companies are heading for a veritable face-off over a decision of the prime minister's office to step in for a comprehensive legislative review of contentious statutes related to patent law in India
You may also be interested in...
India’s Supreme Court Reinstates Pfizer’s Sutent Patent, Orders Review For Patent Office
In a new twist, India’s Supreme Court restores Pfizer’s patent for Sutent, but also removes a restraining order that had prevented Cipla from launching a generic copy.
Exclusive: India’s Supreme Court Reinstates Pfizer’s Sutent Patent; Orders Review For Patent Office
In a new twist, India’s Supreme Court restores Pfizer’s patent for Sutent, but also removes a restraining order that had prevented Cipla from launching a generic copy.
Big Pharma Lukewarm To License Compounds From Indian Start-ups, But A Few Could Be Head Turners
MUMBAI - Faced with the bleak prospect of an almost irreversible pipeline drought, Big Pharma has sharpened its focus on identifying differentiated leads from smaller firms - mainly to in-license early-stage compounds - but it appears there are few Indian start-ups with compounds that fit into this strategic goal